Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia.
Dreisig K, Brünner ED, Marquart HV, Helt LR, Nersting J, Frandsen TL, Jonsson OG, Taskinen M, Vaitkeviciene G, Lund B, Abrahamsson J, Lepik K, Schmiegelow K. Dreisig K, et al. Among authors: abrahamsson j. Pediatr Hematol Oncol. 2021 Apr;38(3):227-238. doi: 10.1080/08880018.2020.1842570. Epub 2020 Nov 18. Pediatr Hematol Oncol. 2021. PMID: 33205673 Clinical Trial.
In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
Lönnerholm G, Thörn I, Sundström C, Frost BM, Abrahamsson J, Behrendtz M, Heldrup J, Jacobsson S, Li A, Olofsson T, Porwit A, Söderhäll S, Larsson R, Forestier E. Lönnerholm G, et al. Among authors: abrahamsson j. Leuk Res. 2009 Jan;33(1):46-53. doi: 10.1016/j.leukres.2008.06.012. Epub 2008 Jul 17. Leuk Res. 2009. PMID: 18639340
Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
Frandsen TL, Abrahamsson J, Lausen B, Vettenranta K, Heyman M, Behrentz M, Castor A, Wehner PS, Frost BM, Andersen EW, Schmiegelow K. Frandsen TL, et al. Among authors: abrahamsson j. Br J Haematol. 2011 Oct;155(2):244-7. doi: 10.1111/j.1365-2141.2011.08835.x. Epub 2011 Aug 18. Br J Haematol. 2011. PMID: 21848519 Free article. Clinical Trial.
Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J, Forestier E, Jahnukainen K, Jónsson ÓG, Zeller B, Palle J, Lönnerholm G, Hasle H, Palmqvist L, Ehrencrona H; Nordic Society of Pediatric Hematology and Oncology (NOPHO). Staffas A, et al. Among authors: abrahamsson j. Blood. 2011 Nov 24;118(22):5905-13. doi: 10.1182/blood-2011-05-353185. Epub 2011 Oct 3. Blood. 2011. PMID: 21967978 Free article.
Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004.
Hasle H, Abrahamsson J, Forestier E, Ha SY, Heldrup J, Jahnukainen K, Jónsson ÓG, Lausen B, Palle J, Zeller B; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Hasle H, et al. Among authors: abrahamsson j. Blood. 2012 Aug 2;120(5):978-84. doi: 10.1182/blood-2012-03-416701. Epub 2012 Jun 22. Blood. 2012. PMID: 22730539 Free article. Clinical Trial.
Outcome of poor response paediatric AML using early SCT.
Wareham NE, Heilmann C, Abrahamsson J, Forestier E, Gustafsson B, Ha SY, Heldrup J, Jahnukainen K, Jónsson ÓG, Lausen B, Palle J, Zeller B, Hasle H. Wareham NE, et al. Among authors: abrahamsson j. Eur J Haematol. 2013 Mar;90(3):187-94. doi: 10.1111/ejh.12051. Epub 2013 Jan 20. Eur J Haematol. 2013. PMID: 23215948
198 results